Mohammed Qatanani
Technik-/Wissenschafts-/F&E-Leiter bei SCHOLAR ROCK HOLDING CORPORATION
Vermögen: 2 Mio $ am 30.04.2024
Aktive Positionen von Mohammed Qatanani
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| SCHOLAR ROCK HOLDING CORPORATION | Technik-/Wissenschafts-/F&E-Leiter | 01.09.2022 | - |
Karriereverlauf von Mohammed Qatanani
Ehemalige bekannte Positionen von Mohammed Qatanani
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| DYNE THERAPEUTICS, INC. | Corporate Officer/Principal | 01.02.2018 | 01.09.2021 |
| ALEXION PHARMACEUTICALS, INC. | Corporate Officer/Principal | 01.07.2015 | 01.01.2018 |
Ausbildung von Mohammed Qatanani
| American University of Beirut | Graduate Degree |
| Baylor College of Medicine | Masters Business Admin |
Statistik
International
| Vereinigte Staaten | 5 |
| Libanon | 2 |
Operativ
| Corporate Officer/Principal | 2 |
| Graduate Degree | 1 |
| Undergraduate Degree | 1 |
Sektoral
| Health Technology | 4 |
| Consumer Services | 3 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| DYNE THERAPEUTICS, INC. | Health Technology |
| SCHOLAR ROCK HOLDING CORPORATION | Health Technology |
| Private Unternehmen | 1 |
|---|---|
Alexion Pharmaceuticals, Inc.
 Alexion Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Alexion Pharmaceuticals, Inc. engages in the business of serving patients and families affected by rare diseases and devastating conditions through the discovery, development, and commercialization of life-changing medicines. The firm also focuses on the development of haematology, nephrology, neurology, metabolic disorders, cardiology, and ophthalmology. The company was founded by Joseph A. Madri, David W. Keiser, Stephen P. Squinto, and Leonard Bell in January 1992 and is headquartered in Boston, MA. | Health Technology |
- Börse
- Insiders
- Mohammed Qatanani
- Erfahrung
